nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—GRIK4—renal system—muscle cancer	0.0205	0.0688	CbGeAlD
Topiramate—GRIK4—head—muscle cancer	0.0137	0.046	CbGeAlD
Topiramate—GRIK4—testis—muscle cancer	0.0132	0.0444	CbGeAlD
Topiramate—GRIK3—tendon—muscle cancer	0.0116	0.0391	CbGeAlD
Topiramate—GRIA4—head—muscle cancer	0.0108	0.0364	CbGeAlD
Topiramate—GRIK3—vagina—muscle cancer	0.0108	0.0363	CbGeAlD
Topiramate—GRIK1—vagina—muscle cancer	0.0103	0.0345	CbGeAlD
Topiramate—GRIK5—head—muscle cancer	0.00998	0.0336	CbGeAlD
Topiramate—GRIK3—head—muscle cancer	0.00998	0.0336	CbGeAlD
Topiramate—GRIK5—testis—muscle cancer	0.00964	0.0324	CbGeAlD
Topiramate—GRIK3—testis—muscle cancer	0.00964	0.0324	CbGeAlD
Topiramate—GRIK1—head—muscle cancer	0.00949	0.0319	CbGeAlD
Topiramate—GRIA3—head—muscle cancer	0.00882	0.0296	CbGeAlD
Topiramate—GRIA3—testis—muscle cancer	0.00852	0.0286	CbGeAlD
Topiramate—GRIA2—embryo—muscle cancer	0.00739	0.0248	CbGeAlD
Topiramate—CA7—renal system—muscle cancer	0.00727	0.0244	CbGeAlD
Topiramate—CA9—tendon—muscle cancer	0.00498	0.0167	CbGeAlD
Topiramate—CA12—renal system—muscle cancer	0.00472	0.0159	CbGeAlD
Topiramate—CA6—head—muscle cancer	0.00471	0.0158	CbGeAlD
Topiramate—GRIA1—head—muscle cancer	0.00471	0.0158	CbGeAlD
Topiramate—GRIA1—testis—muscle cancer	0.00455	0.0153	CbGeAlD
Topiramate—CA9—testis—muscle cancer	0.00412	0.0139	CbGeAlD
Topiramate—CA5B—cardiac atrium—muscle cancer	0.00379	0.0127	CbGeAlD
Topiramate—GRIA2—head—muscle cancer	0.00374	0.0126	CbGeAlD
Topiramate—CA1—renal system—muscle cancer	0.00374	0.0126	CbGeAlD
Topiramate—SCN5A—cardiac atrium—muscle cancer	0.00367	0.0123	CbGeAlD
Topiramate—GRIA2—testis—muscle cancer	0.00361	0.0121	CbGeAlD
Topiramate—SCN1A—head—muscle cancer	0.00341	0.0115	CbGeAlD
Topiramate—GRIK2—head—muscle cancer	0.00338	0.0114	CbGeAlD
Topiramate—CA5B—tendon—muscle cancer	0.0033	0.0111	CbGeAlD
Topiramate—CA2—embryo—muscle cancer	0.0032	0.0108	CbGeAlD
Topiramate—CA12—head—muscle cancer	0.00316	0.0106	CbGeAlD
Topiramate—CA1—C-MYB transcription factor network—MYF6—muscle cancer	0.00308	0.0596	CbGpPWpGaD
Topiramate—CA5B—vagina—muscle cancer	0.00307	0.0103	CbGeAlD
Topiramate—GRIA3—BDNF signaling pathway—KIDINS220—muscle cancer	0.00305	0.059	CbGpPWpGaD
Topiramate—SCN5A—vagina—muscle cancer	0.00297	0.00999	CbGeAlD
Topiramate—CA4—renal system—muscle cancer	0.00292	0.00982	CbGeAlD
Topiramate—CA5B—head—muscle cancer	0.00283	0.00952	CbGeAlD
Topiramate—CA1—bone marrow—muscle cancer	0.00283	0.0095	CbGeAlD
Topiramate—SCN5A—head—muscle cancer	0.00275	0.00923	CbGeAlD
Topiramate—CA5B—testis—muscle cancer	0.00274	0.0092	CbGeAlD
Topiramate—GABRB2—head—muscle cancer	0.00266	0.00894	CbGeAlD
Topiramate—GABRG2—head—muscle cancer	0.00266	0.00894	CbGeAlD
Topiramate—CA4—cardiac atrium—muscle cancer	0.00262	0.0088	CbGeAlD
Topiramate—GABRB2—testis—muscle cancer	0.00257	0.00864	CbGeAlD
Topiramate—CA2—smooth muscle tissue—muscle cancer	0.00252	0.00846	CbGeAlD
Topiramate—CA1—head—muscle cancer	0.0025	0.00841	CbGeAlD
Topiramate—CA2—renal system—muscle cancer	0.00242	0.00814	CbGeAlD
Topiramate—GABRA1—head—muscle cancer	0.00235	0.0079	CbGeAlD
Topiramate—CA4—tendon—muscle cancer	0.00228	0.00767	CbGeAlD
Topiramate—CA4—bone marrow—muscle cancer	0.00221	0.00743	CbGeAlD
Topiramate—GRIA4—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—muscle cancer	0.00221	0.0427	CbGpPWpGaD
Topiramate—CA2—cardiac atrium—muscle cancer	0.00217	0.00729	CbGeAlD
Topiramate—CA4—head—muscle cancer	0.00196	0.00657	CbGeAlD
Topiramate—CYP2C19—vagina—muscle cancer	0.00192	0.00644	CbGeAlD
Topiramate—CA2—tendon—muscle cancer	0.00189	0.00636	CbGeAlD
Topiramate—CA4—testis—muscle cancer	0.00189	0.00635	CbGeAlD
Topiramate—CA2—bone marrow—muscle cancer	0.00183	0.00616	CbGeAlD
Topiramate—GRIA1—BDNF signaling pathway—KIDINS220—muscle cancer	0.00183	0.0353	CbGpPWpGaD
Topiramate—CA2—vagina—muscle cancer	0.00176	0.0059	CbGeAlD
Topiramate—CA2—head—muscle cancer	0.00162	0.00545	CbGeAlD
Topiramate—GRIA3—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—muscle cancer	0.0016	0.031	CbGpPWpGaD
Topiramate—CA2—testis—muscle cancer	0.00157	0.00526	CbGeAlD
Topiramate—CYP3A4—renal system—muscle cancer	0.00156	0.00525	CbGeAlD
Topiramate—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—muscle cancer	0.00147	0.0285	CbGpPWpGaD
Topiramate—GRIA2—N-cadherin signaling events—CNR1—muscle cancer	0.00129	0.0249	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—KIDINS220—muscle cancer	0.00128	0.0247	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—CD34—muscle cancer	0.00123	0.0237	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—MYOD1—muscle cancer	0.00123	0.0237	CbGpPWpGaD
Topiramate—GRIA3—BDNF signaling pathway—CNR1—muscle cancer	0.00101	0.0196	CbGpPWpGaD
Topiramate—GRIA1—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—muscle cancer	0.000961	0.0186	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000815	0.0158	CbGpPWpGaD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000815	0.0158	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MYF6—muscle cancer	0.000773	0.0149	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MYF5—muscle cancer	0.000773	0.0149	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000757	0.0146	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000757	0.0146	CbGpPWpGaD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—IGF2—muscle cancer	0.000704	0.0136	CbGpPWpGaD
Topiramate—Body temperature increased—Vincristine—muscle cancer	0.000686	0.00105	CcSEcCtD
Topiramate—Abdominal pain—Vincristine—muscle cancer	0.000686	0.00105	CcSEcCtD
Topiramate—Liver function test abnormal—Doxorubicin—muscle cancer	0.000685	0.00105	CcSEcCtD
Topiramate—Skin disorder—Etoposide—muscle cancer	0.000683	0.00105	CcSEcCtD
Topiramate—Erectile dysfunction—Methotrexate—muscle cancer	0.000682	0.00105	CcSEcCtD
Topiramate—Hyperhidrosis—Etoposide—muscle cancer	0.00068	0.00104	CcSEcCtD
Topiramate—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000678	0.00104	CcSEcCtD
Topiramate—Abdominal pain upper—Doxorubicin—muscle cancer	0.000678	0.00104	CcSEcCtD
Topiramate—Photosensitivity reaction—Methotrexate—muscle cancer	0.000676	0.00104	CcSEcCtD
Topiramate—Hypokalaemia—Doxorubicin—muscle cancer	0.000676	0.00104	CcSEcCtD
Topiramate—GRIA2—Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity—MDM2—muscle cancer	0.000672	0.013	CbGpPWpGaD
Topiramate—Breast disorder—Doxorubicin—muscle cancer	0.000671	0.00103	CcSEcCtD
Topiramate—Anorexia—Etoposide—muscle cancer	0.000671	0.00103	CcSEcCtD
Topiramate—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000668	0.00103	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000668	0.00103	CcSEcCtD
Topiramate—SCN5A—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000667	0.0129	CbGpPWpGaD
Topiramate—Diarrhoea—Dactinomycin—muscle cancer	0.000665	0.00102	CcSEcCtD
Topiramate—Pneumonia—Methotrexate—muscle cancer	0.000664	0.00102	CcSEcCtD
Topiramate—Nasopharyngitis—Doxorubicin—muscle cancer	0.000664	0.00102	CcSEcCtD
Topiramate—Infestation NOS—Methotrexate—muscle cancer	0.000661	0.00102	CcSEcCtD
Topiramate—Infestation—Methotrexate—muscle cancer	0.000661	0.00102	CcSEcCtD
Topiramate—Depression—Methotrexate—muscle cancer	0.000659	0.00101	CcSEcCtD
Topiramate—Hypotension—Etoposide—muscle cancer	0.000657	0.00101	CcSEcCtD
Topiramate—Gastritis—Doxorubicin—muscle cancer	0.000657	0.00101	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000655	0.00101	CcSEcCtD
Topiramate—Muscular weakness—Doxorubicin—muscle cancer	0.000655	0.00101	CcSEcCtD
Topiramate—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000655	0.00101	CcSEcCtD
Topiramate—CA9—Cellular response to hypoxia—VEGFA—muscle cancer	0.000651	0.0126	CbGpPWpGaD
Topiramate—Renal failure—Methotrexate—muscle cancer	0.000649	0.000998	CcSEcCtD
Topiramate—Abdominal distension—Doxorubicin—muscle cancer	0.000646	0.000993	CcSEcCtD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000644	0.0125	CbGpPWpGaD
Topiramate—Stomatitis—Methotrexate—muscle cancer	0.000644	0.00099	CcSEcCtD
Topiramate—Conjunctivitis—Methotrexate—muscle cancer	0.000642	0.000987	CcSEcCtD
Topiramate—Asthma—Doxorubicin—muscle cancer	0.000642	0.000986	CcSEcCtD
Topiramate—Dysphagia—Doxorubicin—muscle cancer	0.000642	0.000986	CcSEcCtD
Topiramate—Hypersensitivity—Vincristine—muscle cancer	0.00064	0.000983	CcSEcCtD
Topiramate—Eosinophilia—Doxorubicin—muscle cancer	0.000635	0.000976	CcSEcCtD
Topiramate—Paraesthesia—Etoposide—muscle cancer	0.000632	0.000971	CcSEcCtD
Topiramate—Haematuria—Methotrexate—muscle cancer	0.00063	0.000968	CcSEcCtD
Topiramate—Pancreatitis—Doxorubicin—muscle cancer	0.000629	0.000967	CcSEcCtD
Topiramate—Dyspnoea—Etoposide—muscle cancer	0.000627	0.000964	CcSEcCtD
Topiramate—Somnolence—Etoposide—muscle cancer	0.000625	0.000961	CcSEcCtD
Topiramate—Angina pectoris—Doxorubicin—muscle cancer	0.000625	0.00096	CcSEcCtD
Topiramate—Epistaxis—Methotrexate—muscle cancer	0.000623	0.000958	CcSEcCtD
Topiramate—Asthenia—Vincristine—muscle cancer	0.000623	0.000957	CcSEcCtD
Topiramate—Vomiting—Dactinomycin—muscle cancer	0.000618	0.00095	CcSEcCtD
Topiramate—Bronchitis—Doxorubicin—muscle cancer	0.000617	0.000948	CcSEcCtD
Topiramate—Agranulocytosis—Methotrexate—muscle cancer	0.000617	0.000947	CcSEcCtD
Topiramate—Rash—Dactinomycin—muscle cancer	0.000613	0.000942	CcSEcCtD
Topiramate—GRIK4—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000612	0.0118	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000612	0.0118	CbGpPWpGaD
Topiramate—Decreased appetite—Etoposide—muscle cancer	0.000611	0.00094	CcSEcCtD
Topiramate—Pancytopenia—Doxorubicin—muscle cancer	0.000609	0.000936	CcSEcCtD
Topiramate—Gastrointestinal disorder—Etoposide—muscle cancer	0.000607	0.000933	CcSEcCtD
Topiramate—GRIA1—BDNF signaling pathway—CNR1—muscle cancer	0.000607	0.0117	CbGpPWpGaD
Topiramate—Fatigue—Etoposide—muscle cancer	0.000606	0.000932	CcSEcCtD
Topiramate—Constipation—Etoposide—muscle cancer	0.000602	0.000924	CcSEcCtD
Topiramate—Pain—Etoposide—muscle cancer	0.000602	0.000924	CcSEcCtD
Topiramate—Dysuria—Doxorubicin—muscle cancer	0.0006	0.000922	CcSEcCtD
Topiramate—Neutropenia—Doxorubicin—muscle cancer	0.0006	0.000922	CcSEcCtD
Topiramate—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000596	0.000916	CcSEcCtD
Topiramate—Haemoglobin—Methotrexate—muscle cancer	0.000596	0.000916	CcSEcCtD
Topiramate—Diarrhoea—Vincristine—muscle cancer	0.000594	0.000913	CcSEcCtD
Topiramate—Haemorrhage—Methotrexate—muscle cancer	0.000593	0.000911	CcSEcCtD
Topiramate—Hepatitis—Methotrexate—muscle cancer	0.000593	0.000911	CcSEcCtD
Topiramate—Pollakiuria—Doxorubicin—muscle cancer	0.000593	0.000911	CcSEcCtD
Topiramate—Pharyngitis—Methotrexate—muscle cancer	0.000589	0.000905	CcSEcCtD
Topiramate—Urinary tract disorder—Methotrexate—muscle cancer	0.000586	0.0009	CcSEcCtD
Topiramate—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000586	0.0009	CcSEcCtD
Topiramate—Weight increased—Doxorubicin—muscle cancer	0.000584	0.000897	CcSEcCtD
Topiramate—Urethral disorder—Methotrexate—muscle cancer	0.000581	0.000893	CcSEcCtD
Topiramate—Weight decreased—Doxorubicin—muscle cancer	0.00058	0.000892	CcSEcCtD
Topiramate—Feeling abnormal—Etoposide—muscle cancer	0.00058	0.000891	CcSEcCtD
Topiramate—Hyperglycaemia—Doxorubicin—muscle cancer	0.000579	0.000889	CcSEcCtD
Topiramate—Nausea—Dactinomycin—muscle cancer	0.000577	0.000887	CcSEcCtD
Topiramate—Pneumonia—Doxorubicin—muscle cancer	0.000575	0.000884	CcSEcCtD
Topiramate—Gastrointestinal pain—Etoposide—muscle cancer	0.000575	0.000884	CcSEcCtD
Topiramate—Dizziness—Vincristine—muscle cancer	0.000574	0.000882	CcSEcCtD
Topiramate—Infestation NOS—Doxorubicin—muscle cancer	0.000572	0.000879	CcSEcCtD
Topiramate—Infestation—Doxorubicin—muscle cancer	0.000572	0.000879	CcSEcCtD
Topiramate—Visual impairment—Methotrexate—muscle cancer	0.000572	0.000878	CcSEcCtD
Topiramate—GRIK3—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000569	0.011	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000569	0.011	CbGpPWpGaD
Topiramate—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000567	0.000872	CcSEcCtD
Topiramate—Renal failure—Doxorubicin—muscle cancer	0.000562	0.000864	CcSEcCtD
Topiramate—Erythema multiforme—Methotrexate—muscle cancer	0.000561	0.000862	CcSEcCtD
Topiramate—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000561	0.000862	CcSEcCtD
Topiramate—Urticaria—Etoposide—muscle cancer	0.000559	0.000859	CcSEcCtD
Topiramate—Stomatitis—Doxorubicin—muscle cancer	0.000558	0.000857	CcSEcCtD
Topiramate—Abdominal pain—Etoposide—muscle cancer	0.000556	0.000855	CcSEcCtD
Topiramate—Body temperature increased—Etoposide—muscle cancer	0.000556	0.000855	CcSEcCtD
Topiramate—Urinary tract infection—Doxorubicin—muscle cancer	0.000556	0.000854	CcSEcCtD
Topiramate—Conjunctivitis—Doxorubicin—muscle cancer	0.000556	0.000854	CcSEcCtD
Topiramate—Eye disorder—Methotrexate—muscle cancer	0.000554	0.000852	CcSEcCtD
Topiramate—Tinnitus—Methotrexate—muscle cancer	0.000553	0.00085	CcSEcCtD
Topiramate—Vomiting—Vincristine—muscle cancer	0.000552	0.000848	CcSEcCtD
Topiramate—Cardiac disorder—Methotrexate—muscle cancer	0.00055	0.000846	CcSEcCtD
Topiramate—Rash—Vincristine—muscle cancer	0.000548	0.000841	CcSEcCtD
Topiramate—Dermatitis—Vincristine—muscle cancer	0.000547	0.000841	CcSEcCtD
Topiramate—Haematuria—Doxorubicin—muscle cancer	0.000545	0.000838	CcSEcCtD
Topiramate—Headache—Vincristine—muscle cancer	0.000544	0.000836	CcSEcCtD
Topiramate—SCN5A—Developmental Biology—MYF6—muscle cancer	0.000543	0.0105	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MYF5—muscle cancer	0.000543	0.0105	CbGpPWpGaD
Topiramate—Epistaxis—Doxorubicin—muscle cancer	0.00054	0.000829	CcSEcCtD
Topiramate—Angiopathy—Methotrexate—muscle cancer	0.000538	0.000827	CcSEcCtD
Topiramate—Sinusitis—Doxorubicin—muscle cancer	0.000537	0.000825	CcSEcCtD
Topiramate—Immune system disorder—Methotrexate—muscle cancer	0.000536	0.000823	CcSEcCtD
Topiramate—Mediastinal disorder—Methotrexate—muscle cancer	0.000534	0.000821	CcSEcCtD
Topiramate—Agranulocytosis—Doxorubicin—muscle cancer	0.000534	0.00082	CcSEcCtD
Topiramate—Chills—Methotrexate—muscle cancer	0.000532	0.000818	CcSEcCtD
Topiramate—Alopecia—Methotrexate—muscle cancer	0.000524	0.000805	CcSEcCtD
Topiramate—Bradycardia—Doxorubicin—muscle cancer	0.000523	0.000803	CcSEcCtD
Topiramate—Mental disorder—Methotrexate—muscle cancer	0.00052	0.000798	CcSEcCtD
Topiramate—Hypersensitivity—Etoposide—muscle cancer	0.000518	0.000796	CcSEcCtD
Topiramate—Erythema—Methotrexate—muscle cancer	0.000516	0.000793	CcSEcCtD
Topiramate—Malnutrition—Methotrexate—muscle cancer	0.000516	0.000793	CcSEcCtD
Topiramate—Haemoglobin—Doxorubicin—muscle cancer	0.000516	0.000793	CcSEcCtD
Topiramate—Nausea—Vincristine—muscle cancer	0.000516	0.000793	CcSEcCtD
Topiramate—Rhinitis—Doxorubicin—muscle cancer	0.000515	0.000791	CcSEcCtD
Topiramate—Haemorrhage—Doxorubicin—muscle cancer	0.000514	0.000789	CcSEcCtD
Topiramate—Hepatitis—Doxorubicin—muscle cancer	0.000514	0.000789	CcSEcCtD
Topiramate—Hypoaesthesia—Doxorubicin—muscle cancer	0.000511	0.000785	CcSEcCtD
Topiramate—Pharyngitis—Doxorubicin—muscle cancer	0.00051	0.000783	CcSEcCtD
Topiramate—Urinary tract disorder—Doxorubicin—muscle cancer	0.000507	0.000779	CcSEcCtD
Topiramate—Oedema peripheral—Doxorubicin—muscle cancer	0.000506	0.000777	CcSEcCtD
Topiramate—Dysgeusia—Methotrexate—muscle cancer	0.000506	0.000777	CcSEcCtD
Topiramate—Asthenia—Etoposide—muscle cancer	0.000505	0.000776	CcSEcCtD
Topiramate—Connective tissue disorder—Doxorubicin—muscle cancer	0.000505	0.000775	CcSEcCtD
Topiramate—Urethral disorder—Doxorubicin—muscle cancer	0.000503	0.000774	CcSEcCtD
Topiramate—Back pain—Methotrexate—muscle cancer	0.000499	0.000767	CcSEcCtD
Topiramate—SCN1A—Developmental Biology—MYOG—muscle cancer	0.000498	0.00963	CbGpPWpGaD
Topiramate—Pruritus—Etoposide—muscle cancer	0.000498	0.000765	CcSEcCtD
Topiramate—Visual impairment—Doxorubicin—muscle cancer	0.000495	0.00076	CcSEcCtD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—KIT—muscle cancer	0.000493	0.00954	CbGpPWpGaD
Topiramate—Vision blurred—Methotrexate—muscle cancer	0.000487	0.000748	CcSEcCtD
Topiramate—Erythema multiforme—Doxorubicin—muscle cancer	0.000486	0.000746	CcSEcCtD
Topiramate—GRIA4—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000484	0.00936	CbGpPWpGaD
Topiramate—Diarrhoea—Etoposide—muscle cancer	0.000481	0.00074	CcSEcCtD
Topiramate—Eye disorder—Doxorubicin—muscle cancer	0.00048	0.000737	CcSEcCtD
Topiramate—Ill-defined disorder—Methotrexate—muscle cancer	0.000479	0.000736	CcSEcCtD
Topiramate—Tinnitus—Doxorubicin—muscle cancer	0.000479	0.000736	CcSEcCtD
Topiramate—Anaemia—Methotrexate—muscle cancer	0.000477	0.000733	CcSEcCtD
Topiramate—Cardiac disorder—Doxorubicin—muscle cancer	0.000477	0.000732	CcSEcCtD
Topiramate—Flushing—Doxorubicin—muscle cancer	0.000477	0.000732	CcSEcCtD
Topiramate—CA1—C-MYB transcription factor network—KIT—muscle cancer	0.00047	0.00908	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—MDM2—muscle cancer	0.000469	0.00907	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—MDM2—muscle cancer	0.000469	0.00907	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000468	0.00905	CbGpPWpGaD
Topiramate—Angiopathy—Doxorubicin—muscle cancer	0.000466	0.000716	CcSEcCtD
Topiramate—Malaise—Methotrexate—muscle cancer	0.000466	0.000715	CcSEcCtD
Topiramate—Dizziness—Etoposide—muscle cancer	0.000465	0.000715	CcSEcCtD
Topiramate—Immune system disorder—Doxorubicin—muscle cancer	0.000464	0.000713	CcSEcCtD
Topiramate—Vertigo—Methotrexate—muscle cancer	0.000464	0.000713	CcSEcCtD
Topiramate—Mediastinal disorder—Doxorubicin—muscle cancer	0.000463	0.000711	CcSEcCtD
Topiramate—Leukopenia—Methotrexate—muscle cancer	0.000462	0.00071	CcSEcCtD
Topiramate—Chills—Doxorubicin—muscle cancer	0.000461	0.000708	CcSEcCtD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—TP53—muscle cancer	0.000457	0.00883	CbGpPWpGaD
Topiramate—Alopecia—Doxorubicin—muscle cancer	0.000454	0.000697	CcSEcCtD
Topiramate—Cough—Methotrexate—muscle cancer	0.000451	0.000692	CcSEcCtD
Topiramate—Mental disorder—Doxorubicin—muscle cancer	0.00045	0.000691	CcSEcCtD
Topiramate—Convulsion—Methotrexate—muscle cancer	0.000447	0.000687	CcSEcCtD
Topiramate—Vomiting—Etoposide—muscle cancer	0.000447	0.000687	CcSEcCtD
Topiramate—Malnutrition—Doxorubicin—muscle cancer	0.000447	0.000687	CcSEcCtD
Topiramate—Erythema—Doxorubicin—muscle cancer	0.000447	0.000687	CcSEcCtD
Topiramate—Rash—Etoposide—muscle cancer	0.000444	0.000682	CcSEcCtD
Topiramate—Dermatitis—Etoposide—muscle cancer	0.000443	0.000681	CcSEcCtD
Topiramate—Headache—Etoposide—muscle cancer	0.000441	0.000677	CcSEcCtD
Topiramate—Flatulence—Doxorubicin—muscle cancer	0.000441	0.000677	CcSEcCtD
Topiramate—GABRA1—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00044	0.0085	CbGpPWpGaD
Topiramate—Chest pain—Methotrexate—muscle cancer	0.00044	0.000675	CcSEcCtD
Topiramate—Myalgia—Methotrexate—muscle cancer	0.00044	0.000675	CcSEcCtD
Topiramate—Arthralgia—Methotrexate—muscle cancer	0.00044	0.000675	CcSEcCtD
Topiramate—Tension—Doxorubicin—muscle cancer	0.000439	0.000674	CcSEcCtD
Topiramate—Dysgeusia—Doxorubicin—muscle cancer	0.000438	0.000673	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000436	0.000671	CcSEcCtD
Topiramate—GRIK3—Neuronal System—MDM2—muscle cancer	0.000436	0.00843	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—MDM2—muscle cancer	0.000436	0.00843	CbGpPWpGaD
Topiramate—Discomfort—Methotrexate—muscle cancer	0.000434	0.000667	CcSEcCtD
Topiramate—Nervousness—Doxorubicin—muscle cancer	0.000434	0.000667	CcSEcCtD
Topiramate—Back pain—Doxorubicin—muscle cancer	0.000432	0.000664	CcSEcCtD
Topiramate—Muscle spasms—Doxorubicin—muscle cancer	0.00043	0.00066	CcSEcCtD
Topiramate—Confusional state—Methotrexate—muscle cancer	0.000425	0.000653	CcSEcCtD
Topiramate—GRIA2—BDNF signaling pathway—CNR1—muscle cancer	0.000425	0.00821	CbGpPWpGaD
Topiramate—Vision blurred—Doxorubicin—muscle cancer	0.000421	0.000647	CcSEcCtD
Topiramate—Infection—Methotrexate—muscle cancer	0.000419	0.000643	CcSEcCtD
Topiramate—Nausea—Etoposide—muscle cancer	0.000418	0.000642	CcSEcCtD
Topiramate—Ill-defined disorder—Doxorubicin—muscle cancer	0.000415	0.000637	CcSEcCtD
Topiramate—Nervous system disorder—Methotrexate—muscle cancer	0.000413	0.000635	CcSEcCtD
Topiramate—Anaemia—Doxorubicin—muscle cancer	0.000413	0.000635	CcSEcCtD
Topiramate—Thrombocytopenia—Methotrexate—muscle cancer	0.000413	0.000634	CcSEcCtD
Topiramate—Agitation—Doxorubicin—muscle cancer	0.000411	0.000631	CcSEcCtD
Topiramate—Skin disorder—Methotrexate—muscle cancer	0.000409	0.000629	CcSEcCtD
Topiramate—Hyperhidrosis—Methotrexate—muscle cancer	0.000407	0.000626	CcSEcCtD
Topiramate—Malaise—Doxorubicin—muscle cancer	0.000403	0.000619	CcSEcCtD
Topiramate—Vertigo—Doxorubicin—muscle cancer	0.000402	0.000617	CcSEcCtD
Topiramate—Anorexia—Methotrexate—muscle cancer	0.000402	0.000617	CcSEcCtD
Topiramate—Syncope—Doxorubicin—muscle cancer	0.000401	0.000616	CcSEcCtD
Topiramate—Leukopenia—Doxorubicin—muscle cancer	0.0004	0.000615	CcSEcCtD
Topiramate—Palpitations—Doxorubicin—muscle cancer	0.000395	0.000607	CcSEcCtD
Topiramate—Hypotension—Methotrexate—muscle cancer	0.000394	0.000605	CcSEcCtD
Topiramate—Loss of consciousness—Doxorubicin—muscle cancer	0.000393	0.000604	CcSEcCtD
Topiramate—Cough—Doxorubicin—muscle cancer	0.00039	0.000599	CcSEcCtD
Topiramate—Convulsion—Doxorubicin—muscle cancer	0.000387	0.000595	CcSEcCtD
Topiramate—Hypertension—Doxorubicin—muscle cancer	0.000386	0.000593	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000384	0.00059	CcSEcCtD
Topiramate—CA1—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000381	0.00737	CbGpPWpGaD
Topiramate—Insomnia—Methotrexate—muscle cancer	0.000381	0.000586	CcSEcCtD
Topiramate—Chest pain—Doxorubicin—muscle cancer	0.000381	0.000585	CcSEcCtD
Topiramate—Myalgia—Doxorubicin—muscle cancer	0.000381	0.000585	CcSEcCtD
Topiramate—Arthralgia—Doxorubicin—muscle cancer	0.000381	0.000585	CcSEcCtD
Topiramate—Anxiety—Doxorubicin—muscle cancer	0.000379	0.000583	CcSEcCtD
Topiramate—Paraesthesia—Methotrexate—muscle cancer	0.000378	0.000581	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000378	0.000581	CcSEcCtD
Topiramate—Discomfort—Doxorubicin—muscle cancer	0.000376	0.000578	CcSEcCtD
Topiramate—Dyspnoea—Methotrexate—muscle cancer	0.000376	0.000577	CcSEcCtD
Topiramate—Somnolence—Methotrexate—muscle cancer	0.000375	0.000576	CcSEcCtD
Topiramate—Dry mouth—Doxorubicin—muscle cancer	0.000372	0.000572	CcSEcCtD
Topiramate—GRIA4—Neuronal System—MDM2—muscle cancer	0.000371	0.00717	CbGpPWpGaD
Topiramate—Dyspepsia—Methotrexate—muscle cancer	0.000371	0.00057	CcSEcCtD
Topiramate—Confusional state—Doxorubicin—muscle cancer	0.000368	0.000565	CcSEcCtD
Topiramate—Decreased appetite—Methotrexate—muscle cancer	0.000366	0.000563	CcSEcCtD
Topiramate—Oedema—Doxorubicin—muscle cancer	0.000365	0.000561	CcSEcCtD
Topiramate—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000364	0.000559	CcSEcCtD
Topiramate—Fatigue—Methotrexate—muscle cancer	0.000363	0.000558	CcSEcCtD
Topiramate—Infection—Doxorubicin—muscle cancer	0.000362	0.000557	CcSEcCtD
Topiramate—Pain—Methotrexate—muscle cancer	0.00036	0.000554	CcSEcCtD
Topiramate—Shock—Doxorubicin—muscle cancer	0.000359	0.000552	CcSEcCtD
Topiramate—Nervous system disorder—Doxorubicin—muscle cancer	0.000358	0.00055	CcSEcCtD
Topiramate—Thrombocytopenia—Doxorubicin—muscle cancer	0.000357	0.000549	CcSEcCtD
Topiramate—CA1—C-MYB transcription factor network—PTGS2—muscle cancer	0.000357	0.00689	CbGpPWpGaD
Topiramate—Tachycardia—Doxorubicin—muscle cancer	0.000356	0.000547	CcSEcCtD
Topiramate—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000355	0.00687	CbGpPWpGaD
Topiramate—Skin disorder—Doxorubicin—muscle cancer	0.000354	0.000545	CcSEcCtD
Topiramate—Hyperhidrosis—Doxorubicin—muscle cancer	0.000353	0.000542	CcSEcCtD
Topiramate—GRIA3—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000352	0.0068	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MYOG—muscle cancer	0.00035	0.00677	CbGpPWpGaD
Topiramate—Anorexia—Doxorubicin—muscle cancer	0.000348	0.000534	CcSEcCtD
Topiramate—Feeling abnormal—Methotrexate—muscle cancer	0.000347	0.000534	CcSEcCtD
Topiramate—Gastrointestinal pain—Methotrexate—muscle cancer	0.000345	0.000529	CcSEcCtD
Topiramate—Hypotension—Doxorubicin—muscle cancer	0.000341	0.000524	CcSEcCtD
Topiramate—Urticaria—Methotrexate—muscle cancer	0.000335	0.000514	CcSEcCtD
Topiramate—Body temperature increased—Methotrexate—muscle cancer	0.000333	0.000512	CcSEcCtD
Topiramate—Abdominal pain—Methotrexate—muscle cancer	0.000333	0.000512	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000332	0.000511	CcSEcCtD
Topiramate—Insomnia—Doxorubicin—muscle cancer	0.00033	0.000507	CcSEcCtD
Topiramate—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000328	0.00635	CbGpPWpGaD
Topiramate—Paraesthesia—Doxorubicin—muscle cancer	0.000328	0.000503	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—HMGA1—muscle cancer	0.000327	0.00633	CbGpPWpGaD
Topiramate—Dyspnoea—Doxorubicin—muscle cancer	0.000325	0.0005	CcSEcCtD
Topiramate—Somnolence—Doxorubicin—muscle cancer	0.000324	0.000498	CcSEcCtD
Topiramate—Dyspepsia—Doxorubicin—muscle cancer	0.000321	0.000494	CcSEcCtD
Topiramate—Decreased appetite—Doxorubicin—muscle cancer	0.000317	0.000487	CcSEcCtD
Topiramate—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000315	0.000484	CcSEcCtD
Topiramate—Fatigue—Doxorubicin—muscle cancer	0.000315	0.000483	CcSEcCtD
Topiramate—Constipation—Doxorubicin—muscle cancer	0.000312	0.000479	CcSEcCtD
Topiramate—Pain—Doxorubicin—muscle cancer	0.000312	0.000479	CcSEcCtD
Topiramate—Hypersensitivity—Methotrexate—muscle cancer	0.00031	0.000477	CcSEcCtD
Topiramate—SCN1A—Developmental Biology—MYOD1—muscle cancer	0.000308	0.00595	CbGpPWpGaD
Topiramate—Asthenia—Methotrexate—muscle cancer	0.000302	0.000465	CcSEcCtD
Topiramate—CA6—Metabolism—FH—muscle cancer	0.000302	0.00584	CbGpPWpGaD
Topiramate—CA5A—Metabolism—FH—muscle cancer	0.000302	0.00584	CbGpPWpGaD
Topiramate—Feeling abnormal—Doxorubicin—muscle cancer	0.000301	0.000462	CcSEcCtD
Topiramate—CA9—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000299	0.00579	CbGpPWpGaD
Topiramate—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000298	0.000458	CcSEcCtD
Topiramate—Pruritus—Methotrexate—muscle cancer	0.000298	0.000458	CcSEcCtD
Topiramate—Urticaria—Doxorubicin—muscle cancer	0.00029	0.000445	CcSEcCtD
Topiramate—Body temperature increased—Doxorubicin—muscle cancer	0.000288	0.000443	CcSEcCtD
Topiramate—Abdominal pain—Doxorubicin—muscle cancer	0.000288	0.000443	CcSEcCtD
Topiramate—Diarrhoea—Methotrexate—muscle cancer	0.000288	0.000443	CcSEcCtD
Topiramate—CA7—Metabolism—FH—muscle cancer	0.000282	0.00545	CbGpPWpGaD
Topiramate—CA5B—Metabolism—FH—muscle cancer	0.000282	0.00545	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MED12—muscle cancer	0.000281	0.00544	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.00028	0.00542	CbGpPWpGaD
Topiramate—Dizziness—Methotrexate—muscle cancer	0.000279	0.000428	CcSEcCtD
Topiramate—GRIA3—Neuronal System—MDM2—muscle cancer	0.00027	0.00521	CbGpPWpGaD
Topiramate—Hypersensitivity—Doxorubicin—muscle cancer	0.000269	0.000413	CcSEcCtD
Topiramate—Vomiting—Methotrexate—muscle cancer	0.000268	0.000412	CcSEcCtD
Topiramate—Rash—Methotrexate—muscle cancer	0.000266	0.000408	CcSEcCtD
Topiramate—Dermatitis—Methotrexate—muscle cancer	0.000265	0.000408	CcSEcCtD
Topiramate—Headache—Methotrexate—muscle cancer	0.000264	0.000406	CcSEcCtD
Topiramate—Asthenia—Doxorubicin—muscle cancer	0.000262	0.000402	CcSEcCtD
Topiramate—CA12—Metabolism—FH—muscle cancer	0.000261	0.00505	CbGpPWpGaD
Topiramate—Pruritus—Doxorubicin—muscle cancer	0.000258	0.000397	CcSEcCtD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000256	0.00496	CbGpPWpGaD
Topiramate—Nausea—Methotrexate—muscle cancer	0.00025	0.000385	CcSEcCtD
Topiramate—Diarrhoea—Doxorubicin—muscle cancer	0.00025	0.000384	CcSEcCtD
Topiramate—Dizziness—Doxorubicin—muscle cancer	0.000241	0.000371	CcSEcCtD
Topiramate—Vomiting—Doxorubicin—muscle cancer	0.000232	0.000356	CcSEcCtD
Topiramate—Rash—Doxorubicin—muscle cancer	0.00023	0.000353	CcSEcCtD
Topiramate—Dermatitis—Doxorubicin—muscle cancer	0.00023	0.000353	CcSEcCtD
Topiramate—Headache—Doxorubicin—muscle cancer	0.000229	0.000351	CcSEcCtD
Topiramate—Nausea—Doxorubicin—muscle cancer	0.000217	0.000333	CcSEcCtD
Topiramate—SCN5A—Developmental Biology—MYOD1—muscle cancer	0.000216	0.00418	CbGpPWpGaD
Topiramate—GRIA1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000211	0.00407	CbGpPWpGaD
Topiramate—CA4—Metabolism—FH—muscle cancer	0.000208	0.00403	CbGpPWpGaD
Topiramate—CA2—Metabolism—FH—muscle cancer	0.0002	0.00386	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MED12—muscle cancer	0.000198	0.00382	CbGpPWpGaD
Topiramate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000197	0.00382	CbGpPWpGaD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000196	0.00379	CbGpPWpGaD
Topiramate—GRIK2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000193	0.00373	CbGpPWpGaD
Topiramate—CA1—Metabolism—FH—muscle cancer	0.000192	0.0037	CbGpPWpGaD
Topiramate—CA5A—Metabolism—MED12—muscle cancer	0.000171	0.0033	CbGpPWpGaD
Topiramate—CA6—Metabolism—MED12—muscle cancer	0.000171	0.0033	CbGpPWpGaD
Topiramate—CA9—Metabolism—FH—muscle cancer	0.000168	0.00326	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—MDM2—muscle cancer	0.000161	0.00312	CbGpPWpGaD
Topiramate—CA5B—Metabolism—MED12—muscle cancer	0.000159	0.00308	CbGpPWpGaD
Topiramate—CA7—Metabolism—MED12—muscle cancer	0.000159	0.00308	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ENO2—muscle cancer	0.000156	0.00301	CbGpPWpGaD
Topiramate—CA6—Metabolism—ENO2—muscle cancer	0.000156	0.00301	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—FOXO1—muscle cancer	0.000154	0.00299	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—MDM2—muscle cancer	0.000148	0.00286	CbGpPWpGaD
Topiramate—CA12—Metabolism—MED12—muscle cancer	0.000148	0.00285	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000147	0.00285	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000147	0.00285	CbGpPWpGaD
Topiramate—CA7—Metabolism—ENO2—muscle cancer	0.000145	0.00281	CbGpPWpGaD
Topiramate—CA5B—Metabolism—ENO2—muscle cancer	0.000145	0.00281	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000135	0.0026	CbGpPWpGaD
Topiramate—CA12—Metabolism—ENO2—muscle cancer	0.000135	0.0026	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CDKN2A—muscle cancer	0.000134	0.00259	CbGpPWpGaD
Topiramate—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000133	0.00257	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—MDM2—muscle cancer	0.00013	0.00252	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000124	0.00241	CbGpPWpGaD
Topiramate—CA4—Metabolism—MED12—muscle cancer	0.000118	0.00228	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.000118	0.00228	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—MDM2—muscle cancer	0.000113	0.00218	CbGpPWpGaD
Topiramate—CA2—Metabolism—MED12—muscle cancer	0.000113	0.00218	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000111	0.00214	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—FOXO1—muscle cancer	0.000109	0.0021	CbGpPWpGaD
Topiramate—CA1—Metabolism—MED12—muscle cancer	0.000108	0.00209	CbGpPWpGaD
Topiramate—CA4—Metabolism—ENO2—muscle cancer	0.000107	0.00208	CbGpPWpGaD
Topiramate—CA2—Metabolism—ENO2—muscle cancer	0.000103	0.00199	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000101	0.00196	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—VEGFA—muscle cancer	9.88e-05	0.00191	CbGpPWpGaD
Topiramate—CA1—Metabolism—ENO2—muscle cancer	9.87e-05	0.00191	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—VEGFA—muscle cancer	9.86e-05	0.00191	CbGpPWpGaD
Topiramate—CA9—Metabolism—MED12—muscle cancer	9.52e-05	0.00184	CbGpPWpGaD
Topiramate—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	8.86e-05	0.00171	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—MDM2—muscle cancer	8.85e-05	0.00171	CbGpPWpGaD
Topiramate—CA9—Metabolism—ENO2—muscle cancer	8.68e-05	0.00168	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—MDM2—muscle cancer	8.48e-05	0.00164	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	8.2e-05	0.00158	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—MDM2—muscle cancer	7.76e-05	0.0015	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—TP53—muscle cancer	7.46e-05	0.00144	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—VEGFA—muscle cancer	7.04e-05	0.00136	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—VEGFA—muscle cancer	6.93e-05	0.00134	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—MDM2—muscle cancer	6.78e-05	0.00131	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.98e-05	0.00116	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTGS2—muscle cancer	5.42e-05	0.00105	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTGS2—muscle cancer	5.42e-05	0.00105	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTGS2—muscle cancer	5.06e-05	0.000979	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTGS2—muscle cancer	5.06e-05	0.000979	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—VEGFA—muscle cancer	4.95e-05	0.000957	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—FH—muscle cancer	4.71e-05	0.000911	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTGS2—muscle cancer	4.69e-05	0.000907	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTGS2—muscle cancer	3.74e-05	0.000723	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTGS2—muscle cancer	3.59e-05	0.000693	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTGS2—muscle cancer	3.44e-05	0.000665	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTGS2—muscle cancer	3.02e-05	0.000584	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—FH—muscle cancer	2.84e-05	0.000548	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—MED12—muscle cancer	2.66e-05	0.000515	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ENO2—muscle cancer	2.43e-05	0.00047	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.9e-05	0.000367	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—MED12—muscle cancer	1.6e-05	0.00031	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ENO2—muscle cancer	1.46e-05	0.000282	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTGS2—muscle cancer	8.46e-06	0.000164	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTGS2—muscle cancer	5.09e-06	9.83e-05	CbGpPWpGaD
